ALK and non-small cell lung carcinoma: In some ways, the trial was especially well-suited to a decentralized, home-run model: (i) the targeted alteration was ultra-rare but could be identified by an NGS assay used nationally; and (ii) the ALK inhibitor tested – alectinib – was already FDA-approved (for the treatment of ALK aberrant NSCLC)32, is oral, and is well tolerated.